Financial Performance
5Y price score: 601
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 667.1%
%
ㅤ
By default your notes are visible only to you.
723.6
52-week range
1121.5
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
5.3 %
Dividend Yield TTM
0.3 %
Market cap $
$ 124,669
Price / Earnings TTM
27.8
Price / Book TTM
(31.8)
PEG TTM
0.6
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
26.4 %
389.3 %
667.1 %
Free cash flow per share growth
41.3 %
79.5 %
239.1 %
Earnings per share growth
17 %
242 %
295.7 %
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2027 Q2 (Nov 4, 2026)
1) Strong Financial Performance
- Revenues increased by 8% YoY to $111 billion, driven by growth across all segments.
- Adjusted earnings per diluted share rose 18% YoY to $11.68.
- North American Pharmaceuticals segment revenues grew 6%, with specialty products and GLP-1 medications contributing significantly.
- Oncology and multispecialty revenues surged 24%, supported by strong utilization and distribution of specialty products.
- The company raised its fiscal 27 adjusted earnings guidance to $45.60 to $46.40 from $44.20 to $45.
2) Strategic Acquisitions and Investments
- McKesson completed the acquisition of Precision Medicine Group for approximately $2.25 billion, expected to be accretive to earnings by $0.10 to $0.20 in fiscal 27.
- The acquisition enhances McKesson's oncology strategy and biopharma services, integrating clinical research expertise and market access capabilities.
- A strategic investment of $1.4 billion for a 49% minority interest in Option Care Health aims to expand access to home and community-based care.
- Both acquisitions align with McKesson's focus on enhancing patient access to innovative therapies.
3) Operational Excellence and Market Trends
- The company reported strong operational leverage, with operating expenses as a percentage of gross profit improving by 141 basis points YoY.
- Continued growth in prescription volumes, particularly in specialty and GLP-1 medications, supports the positive outlook for North American Pharmaceuticals.
- McKesson's distribution network and technology investments are expected to enhance service reliability and efficiency, driving sustainable long-term growth.
4) Challenges and Market Dynamics
- The company faces potential impacts from changes in the 340B program and ongoing branded-to-generic conversions, which may affect revenue growth.
- The dynamic policy environment, particularly post-election, may influence operational strategies and customer behaviors, although McKesson remains committed to supporting its partners through these changes.
- Lower branded pharmaceutical pricing due to wholesale acquisition cost decreases may continue to pressure revenue growth.
5) Guidance and Outlook
- McKesson anticipates revenue growth of 6% to 10% and operating profit growth of 12% to 16% for fiscal 27.
- The North American Pharmaceuticals segment is expected to see revenue growth of 5% to 9%, while oncology and multispecialty may grow 20% to 24%.
- The company plans to maintain a disciplined capital allocation strategy, including $5 billion in share repurchases for the fiscal year.
- The transcript lacks specific details on the long-term impact of the acquisitions on operational margins and integration strategies.
Bottom line: McKesson's strong Q2 results and strategic acquisitions position the company for continued growth, despite potential market challenges. The raised earnings guidance reflects confidence in operational execution and market demand, making it an attractive prospect for shareholders.
Annual Reports, Presentations And IR Contacts
Go to the websiteMcKesson Corporation — Financial Overview, Stock Price, Market Cap
McKesson Corporation is a company . Founded in 1833. As of November 12, 2026, the company's market capitalization is $124669314030 with a current stock price of $1079.79.
